Skip to menu Skip to content Skip to footer
News

UQ team develop model for correct drug use for child transplant recipients

19 April 2000

University of Queensland researchers have developed a mathematical model to ensure correct anti-rejection drug dosages for babies and children receiving liver transplants.

The research team, headed by School of Pharmacy head Professor Susan Tett, discovered children receiving cut-down adult liver transplants had a slower metabolism than those receiving rarely donated child livers.

"In other words, children receiving a part of an adult liver could not process drugs through their bodies at the same rate as young patients receiving children's livers and were at risk of accumulating immunosuppressant drugs in their systems over time," she said.

The preferred immunosuppressant for these children, tacrolimus, must be administered just after surgery and then twice a day for their rest of their lives. Too little of the drug can result in liver rejection and potential death while too much can have unpleasant side-effects including seizures, according to Professor Tett.

"Adult livers are more commonly donated for transplant with only a third of one liver required for babies and young children and two-thirds then available for transplant into an adult recipient," she said.

Funded by a three-year, $142,000 National Health and Medical Research Council grant, researchers analysed data from 35 cases of babies receiving liver transplants through Brisbane's Royal Children's Hospital.

The mathematical model of drug clearance rates from child liver transplant recipients is being further tested before a computer model is developed for doctors and surgeons to assist in choosing the correct drug dose.

"Doctors will eventually be able to type variables such as whether the donor liver is from an adult or child as well as patient details such as weight into the program and be given the optimal drug dosage," Professor Tett said.

The research team included Queensland Liver Transplant Unit Director Associate Professor Steve Lynch, Princess Alexandra Hospital scientists Paul Taylor and Paul Salin, Pharmacy School PhD student Christine Staatz and research assistant Charlene Willis.

The same UQ team in conjunction with PA Hospital clinical pharmacologist Dr Peter Pillans have also developed a strategy for monitoring and determining optimal dosage of the immunosuppressant drug mycophenolate mofetil in adult kidney transplant recipients.

For more information, contact Professor Susan Tett (telephone 07 3365 3191, email s.tett@pharmacy.uq.edu.au) or Shirley Glaister at UQ Communications (telephone 07 3365 2339).

Enquiries can also be directed to communications@mailbox.uq.edu.au

Related articles

Hand-coloured drawing of the town of Hobart in the 1800s, depicting grassy plains, the beach and a small town in the distance.
Analysis

What was Australia’s first novel?

The first novel written and published in Australia is a multifaceted work of autobiographical and historical significance, a convict narrative and, arguably, Australia’s first work of crime fiction.
15 October 2026
Three researchers wearing blue protective lab gowns stand among rows of potted chickpea plants inside a controlled-environment plant research facility.

Turning up the heat on chickpea yield

A University of Queensland study has outlined a practical pathway for accelerating the development of heat adapted chickpeas using data from new ‘omic’ technologies. PhD candidate Callum Jamie said the suite of technologies offered tremendous opportunities to understand how a complex trait like heat tolerance works. “The narrow genetic diversity in the elite chickpea gene pool has limited conventional breeding’s effectiveness for stress tolerance,” Mr Jamie said. “These technologies have improved our capacity to dissect trait architecture and phenotype secondary traits but their use in chickpeas has been limited.” The technologies include genomics, epigenomics, transcriptomics, proteomics, metabolomics, phenomics and enviromics, and help provide a comprehensive picture of biological systems. Epigenomics helps understand what controls gene activity; transcriptomics considers gene expression; proteomics protein production; metabolomics looks at biochemical processes; phenomics observes traits; and enviromics considers environmental factors influencing outcomes. Mr Jamie said previous studies had focused on just 1 to 2 -omic datasets, a small number of genotypes, and single tissues. This has meant it was hard to infer what results meant for trait architecture and mechanisms and the ability to extrapolate the information to breeding populations was limited. There have also been challenges around cost, scalability and integrating very different types of data to make the technologies useful. To overcome the hurdles, Mr Jamie’s research at the Queensland Alliance for Agriculture and Food Innovation has resulted in a proposed staged approach. It would start with genomic prediction and phenotyping, before adding -omic layers as costs fall and unknowns were resolved. “These technologies are novel and we still don’t know which information provides added value and how best to integrate all of this data to achieve an outcome,” Mr Jamie said. His PhD is supported by the Grains Research and Development Corporation (GRDC) and the International Research Training Group (IRTG) Accelerating Crop Genetic Gain and is aligned to a project which aims to fast-track the development of chickpea varieties adapted to high temperatures. Project leader Dr Millicent Smith said heat stress causes severe yield implications through flower and pod loss, reduced pollen viability and impaired grain filling. “Late sown chickpea is particularly in the firing line across most of Australia's crop in southern Queensland and northern New South Wales,” Dr Smith said. “We want to ensure that Australian growers maintain their competitive edge. “New varieties with improved genetics to cope with heat stress are essential for the future. “This work, suggesting a staged approach to utilising the new -omic technologies, is an exciting frontier.” The research was published by Food and Energy Security. Callum Jamie’s PhD is supported by the Grains Research and Development Corporation (GRDC) and the International Research Training Group (IRTG) Accelerating Crop Genetic Gain.
15 October 2026

Media contact

Subscribe to UQ News

Get the latest from our newsroom.